Protocol Ledger

NCT07098988 · Phase II · RECRUITING

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Interventional Phase II clinical trial protocol NCT07098988 sponsored by CatalYm in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-01 Enrollment: 107 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07098988
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)107 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07098988
Protocol FieldVerified Registry Value
NCT IdentifierNCT07098988
Consolidated Lead SponsorCatalYm
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment107 participants (ESTIMATED)
Registered Start Date2025-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI